Genfit And Genkyotex In PBC: The End Of Phase 2
(WorldNews Health)

Introduction Conventional FDA-approved therapeutics, UDCA and obeticholic acid, for PBC are associated side effects that some patients find intolerable. Moreover, patients with moderate and advanced PBC remain underserved patient populations. GKT831 by Genkyotex [GKTX.PA] is one of the few or the only investigative drug candidate with a specific focus on all patients group, mild, moderate, and advanced PBC. Seladelpar was effective in patients with mild and moderate PBC based on the 52-week Phase 2b data. Genkyotex has proposed that GKT831 could exert direct anti-fibrotic effects on myofibroblasts in a broad PBC patient population comprising mild, moderate, and advanced PBC to regress...